Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 19;15(2):e0228669.
doi: 10.1371/journal.pone.0228669. eCollection 2020.

Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and Swaziland

Muthoni Mwaura  1 , Kekeletso Kao  2 , Jesse Wambugu  2 , Andre Trollip  2 , Welile Sikhondze  3 , Eunice Omesa  4 , Sindi Dlamini  5 , Nompumelelo Mzizi  3 , Muyalo Dlamini  3 , Busizwe Sibandze  3 , Brian Dlamini  3 , Heidi Albert  2 , Wybo Dondorp  1 , Nora Engel  1
Affiliations

Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and Swaziland

Muthoni Mwaura et al. PLoS One. .

Abstract

Implementing new diagnostics in public health programs can involve difficult trade-off decisions between individual patient benefits and public health considerations. Such decision-making processes are often not documented and may not include engagement of affected communities. This paper examines the perspectives of stakeholders on the trade-off between over-treatment and missed diagnosis captured during decision-making workshops on the transition from use of Xpert MTB/RIF to diagnose tuberculosis to Xpert MTB/RIF Ultra in Kenya and Swaziland. Xpert MTB/RIF Ultra has an overall increase in sensitivity but a decrease in specificity when compared to its predecessor. We conducted a qualitative study using four focus group discussions with a total of 47 participants and non-participant observation. The analysis reveals how participants deemed Xpert MTB/RIF Ultra's reduced specificity vis-à-vis its increased sensitivity to be an acceptable trade-off. The way participants assessed this trade-off was shaped by their experiences with the general uncertainty of all diagnostic tests, alternative testing options, historical evolution of diagnostic practices, epidemiological factors and resource constraints. In assessing the trade-off community and individual benefit and harm was frequently discussed together. Qualitative research on stakeholder engagement activities for diagnostic development and implementation can identify everyday experiences and situate assessments and perspectives of key stakeholders and as such aid in decision-making, improving implementation as well as patient outcomes. Further research is needed on the intended and unintended consequences of such engagement activities, how findings are being incorporated by decision-makers, and the impact on programmatic implementation.

PubMed Disclaimer

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: FIND collaborated with Cepheid and Rutgers to develop the Xpert MTB/RIF Ultra cartridge. FIND also led the evaluation studies to get the cartridge endorsed by WHO thus increasing acceptability of the cartridges in the countries of intended use. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. WHO recommended algorithm for diagnosing all presumptive TB patients with Xpert MTB/RIF.
See this image and copyright information in PMC

References

    1. World Health Organization. Global Tuberculosis Report 2017. Geneva; 2017. Available from: https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf
    1. Global Laboratory Initiative. Planning for country transition to Xpert® MTB/RIF Ultra cartridges. Geneva; 2017. Available from: http://www.stoptb.org/wg/gli/assets/documents/gli_ultra.pdf
    1. Lawn SD, Brooks S V, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and Rifampicin resistance before antiretroviral thearpy using Xpert MTB/RIF assay: A prospective study. PLoS Med. 2011;8 e1001067. 10.1371/journal.pmed.1001067 - DOI - PMC - PubMed
    1. Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using Xpert MTB/RIF assay. Expert Rev Anti Infect Ther. 2012;10: 631–635. 10.1586/eri.12.43 - DOI - PMC - PubMed
    1. Zar HJ, Workman L, Isaacs W, Dheda K, Zemanay W, Nicol MP. Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study. Lancet Glob Heal. 2013;1: e97–e104. - PubMed

Publication types

Substances